Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Similar Items

• Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
  by: Bosch J.; Eikelboom J.W.; Connolly S.J.; Bruns N.C.; Lanius V.; Yuan F.; Misselwitz F.; Chen E.; Diaz R.; Alings M.; Lonn E.M.; Widimsky P.; Hori M.; Avezum A.; Piegas L.S.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Liang Y.; Liu L.; Zhu J.; Maggioni A.P.; Lopez-Jaramillo P.; O'Donnell M.; Fox K.A.A.; Kakkar A.; Parkhomenko A.N.; Ertl G.; Störk S.; Keltai K.; Keltai M.; Ryden L.; Dagenais G.R.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Verhamme P.B.; Vinereanu D.; Kim J.-H.; Ha J.-W.; Tonkin A.M.; Varigos J.D.; Lewis B.S.; Felix C.; Yusoff K.; Steg P.G.; Aboyans V.; Metsarinne K.P.; Anand S.S.; Hart R.G.; Lamy A.; Moayyedi P.; Leong D.P.; Sharma M.; Yusuf S.
  Published: (2017)
• Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study
  by: Schwalm J.-D.R.; McCready T.; Lamelas P.; Musa H.; Lopez-Jaramillo P.; Yusoff K.; McKee M.; Camacho P.A.; Lopez-Lopez J.; Majid F.; Thabane L.; Islam S.; Yusuf S.
  Published: (2018)
• Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
  by: Eikelboom J.W.; Bosch J.; Connolly S.J.; Tyrwitt J.; Fox K.A.A.; Muehlhofer E.; Neumann C.; Tasto C.; Bangdiwala S.I.; Diaz R.; Alings M.; Dagenais G.R.; Leong D.P.; Lonn E.M.; Avezum A.; Piegas L.S.; Widimsky P.; Parkhomenko A.N.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Lopez-Jaramillo P.; Rydén L.; Pogosova N.; Keltai K.; Keltai M.; Ertl G.; Stoerk S.; Dans A.L.; Lanas F.; Liang Y.; Zhu J.; Torp-Pedersen C.; Maggioni A.P.; Commerford P.J.; Guzik T.J.; Vanassche T.; Verhamme P.; O'donnell M.; Tonkin A.M.; Varigos J.D.; Vinereanu D.; Felix C.; Kim J.-H.; Ibrahim K.S.; Lewis B.S.; Metsarinne K.P.; Aboyans V.; Steg P.G.; Hori M.; Kakkar A.; Anand S.S.; Lamy A.; Sharma M.; Yusuf S.
  Published: (2022)
• A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial
  by: Schwalm J.-D.; McCready T.; Lopez-Jaramillo P.; Yusoff K.; Attaran A.; Lamelas P.; Camacho P.A.; Majid F.; Bangdiwala S.I.; Thabane L.; Islam S.; McKee M.; Yusuf S.
  Published: (2019)
• Polypill with or without aspirin in persons without cardiovascular disease
  by: Yusuf S.; Joseph P.; Dans A.; Gao P.; Teo K.; Xavier D.; Lopez-Jaramillo P.; Yusoff K.; Santoso A.; Gamra H.; Talukder S.; Christou C.; Girish P.; Yeates K.; Xavier F.; Dagenais G.; Rocha C.; McCready T.; Tyrwhitt J.; Bosch J.; Pais P.
  Published: (2021)